TICKERNERD
Menu
MDXGMDXGHealthcare · Biotechnology

MDXG Stock Forecast: MiMedx Group, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$4.27
+3.39% on the day

The 5 Wall Street analysts covering MiMedx Group, Inc. hold a median 12-month price target of $6 — +40.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$615.1M
Ticker Nerd rank
71 / 100
Median analyst target
$6.00
Analysts covering
5
Total return, dividends reinvested
1W
+0.2%
1M
+8.1%
YTD
−36.9%
1Y
−40.4%
From 52W high
−46.4%
From 52W low
+38.2%
$3.09
$7.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDXG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MiMedx Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Value
90
Volatility
89
Quality
80
Issuance
74
Size
50
Growth
38
Revisions
29
Momentum
18

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (18): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own MiMedx Group, Inc. — and when they’d sell — is the membership.

Wall Street

MDXG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDXG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00Oct 25Jan 26Apr 26Jul 26MDXGHigh $8.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $5.00Median $6.00High $8.00

The green dot is the last close — the median target sits +40.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Apr 2026CitizensMaintainsMarket Outperform$7.00 → $6.00
20 Apr 2026CitizensMaintainsMarket Outperform—
17 Apr 2026Craig-HallumMaintainsBuy—
23 Feb 2026CitizensInitiatesMarket Outperform—
17 Feb 2026Cantor FitzgeraldMaintainsOverweight—
20 Jan 2026Lake StreetMaintainsBuy—
17 Dec 2025MizuhoMaintainsOutperform—
31 July 2025Cantor FitzgeraldMaintainsOverweight—
15 July 2025Cantor FitzgeraldReiteratesOverweight—
27 Feb 2025Cantor FitzgeraldReiteratesOverweight—
1 Aug 2024Cantor FitzgeraldReiteratesOverweight—
1 Aug 2024Craig-HallumMaintainsBuy—
2 July 2024Cantor FitzgeraldInitiatesOverweight—
1 May 2024HC Wainwright & Co.ReiteratesBuy—
7 Mar 2024Lake StreetInitiatesBuy—
1 Mar 2024MizuhoMaintainsBuy—
31 Oct 2023MizuhoMaintainsBuy—
27 Oct 2023Craig-HallumInitiatesBuy—
2 Aug 2023HC Wainwright & Co.MaintainsBuy—
2 Aug 2023MizuhoMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MDXG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

MiMedx Group, Inc. (MDXG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
103.3×

Cheaper than 7% of US stocks

Price / sales
1.7×

Cheaper than 57% of US stocks

Price / book
2.5×

Cheaper than 38% of US stocks

EV / EBITDA
23.7×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
−34.7%

Higher than 8% of US stocks

Earnings growth (YoY)
−34.7%

Higher than 14% of US stocks

Gross margin
69.0%

Higher than 82% of US stocks

Operating margin
−28.7%

Higher than 21% of US stocks

Net margin
1.8%

Higher than 51% of US stocks

Returns & dividend
Return on equity
2.9%

Higher than 49% of US stocks

Return on assets
1.9%

Higher than 58% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MDXG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MDXGMiMedx Group, Inc.$615.1M
71
ALLOAllogene Therapeutics, Inc.$622.8M
84
CTNMContineum Therapeutics, Inc.$600.3M
66
RGNXREGENXBIO, Inc.$632.9M
30
NGNENeurogene, Inc.$634.8M
62
IMMXImmix Biopharma, Inc.$592.3M
44
CRMDCorMedix, Inc.$589.9M
65
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDXG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest MDXG news & analysis

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

Business Wire · 3 Aug 2026neutral

Law firm Kahn Swick & Foti, LLC announced it is investigating the adequacy of the price and process in the proposed acquisition of Sanara MedTech Inc. by MiMedx Group, Inc. Under the deal terms, Sanara shareholders would receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share.

Why it matters — The investigation introduces potential legal scrutiny and possible delays or revisions to MiMedx's proposed acquisition of Sanara MedTech, which MDXG watchers will want to monitor.

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

MiMedx Group held its Q2 2026 earnings call, and the transcript of that call was published on Seeking Alpha.

Why it matters — Earnings calls provide direct insight into MiMedx's financial performance and management's outlook, which is key for shareholders tracking the company's progress.

MiMedx Group Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

MiMedx Group announced it has agreed to acquire Sanara MedTech at $35 per share, with the deal expected to close by the end of 2026. The acquisition was disclosed alongside the company's second-quarter results, which showed sequential improvement in wound-care and continued growth in surgical sales.

Why it matters — MDXG watchers would monitor the Sanara MedTech acquisition as a significant strategic move expected to close by end of 2026, alongside improving performance in the company's wound-care and surgical segments.

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

GlobeNewsWire · 29 July 2026neutral

MIMEDX reported second quarter 2026 net sales of $64 million and reiterated its full-year financial outlook on a standalone basis. The company also announced plans to acquire Sanara MedTech and scheduled a conference call for July 29, 2026.

Why it matters — MDXG watchers would care because the company reported quarterly results, reaffirmed its annual outlook, and disclosed an acquisition plan for Sanara MedTech.

MIMEDX to Acquire Sanara MedTech

GlobeNewsWire · 29 July 2026positive

MiMedx Group has entered into a definitive merger agreement to acquire all outstanding shares of Sanara MedTech in a cash and stock transaction valued at $35 per share, with a total enterprise value of approximately $350 million.

Why it matters — The acquisition nearly doubles MIMEDX's surgical revenue, is immediately accretive to revenue growth and margins, and is expected to generate over $20 million in run-rate cost synergies, significantly expanding the company's surgical footprint.

FAQ

Frequently asked questions about MDXG stock

What is the MDXG stock price forecast for 2026-2027?

The 5 Wall Street analysts covering MiMedx Group, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDXG stock a buy right now?

Of the 5 analysts covering MiMedx Group, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MiMedx Group, Inc. 71 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDXG?

As at 1 Aug 2026, MiMedx Group, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will MDXG stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +40.5% from the last close, and Ticker Nerd's factor model ranks MiMedx Group, Inc. 71 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDXG stock forecast for 2030?

No analyst covering MiMedx Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has MDXG stock performed over the past year?

MiMedx Group, Inc. returned -40.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MiMedx Group, Inc. do?

MiMedx Group, Inc. is a leading biopharmaceutical company specializing in regenerative medicine.

What is the latest news on MDXG?

The most recent item we track (Business Wire, 3 Aug 2026): "Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI". Law firm Kahn Swick & Foti, LLC announced it is investigating the adequacy of the price and process in the proposed acquisition of Sanara MedTech Inc. by MiMedx Group, Inc. Under the deal terms, Sanara shareholders would receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share.

Company

About MiMedx Group, Inc.

MiMedx Group, Inc. is a leading biopharmaceutical company specializing in regenerative medicine. The company's primary focus is on the development and commercialization of innovative bioimplants derived from human placental tissues. MiMedx's products are designed to enhance healing by leveraging the innate properties of placental tissue to treat a variety of conditions, including chronic and hard-to-heal wounds, surgical sites, and musculoskeletal injuries. These advanced solutions cater to the needs of healthcare providers across the wound care, ophthalmology, and orthopedics sectors. By addressing critical gaps in the treatment of complex medical conditions, MiMedx plays a significant role in advancing regenerative medicine technologies. The company's commitment to research and development in tissue engineering continues to drive its influence in the healthcare market, offering solutions that not only improve patient outcomes but also reduce overall treatment costs. Through its cutting-edge products and continuous innovation, MiMedx Group, Inc. contributes meaningfully to the evolving landscape of biopharmaceuticals.

CEO Mr. Joseph H. Capper · 808 employees · United States · https://www.mimedx.com